Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$43.30-0.9%$39.66$31.72▼$45.59$88.10B0.535.17 million shs13.11 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-4.09%+10.35%+12.18%+14.11%+10.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$43.30-0.9%$39.66$31.72▼$45.59$88.10B0.535.17 million shs13.11 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-4.09%+10.35%+12.18%+14.11%+10.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 1.88Reduce$37.38-13.69% DownsideCurrent Analyst Ratings BreakdownLatest GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025GSKGSKWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$40.10B2.20$5.31 per share8.16$8.07 per share5.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$2.1620.059.312.2710.81%49.22%11.31%10/29/2025 (Estimated)Latest GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025GSKGSK$1.22N/AN/AN/A$8.21 billionN/A7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.683.88%N/A77.78%N/ALatest GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.070.870.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK68,6292.03 billion1.83 billionOptionableGSK HeadlinesRecent News About These CompaniesWill Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?October 3 at 1:11 PM | zacks.comWhy GSK (GSK) is a Top Value Stock for the Long-TermOctober 2 at 10:41 AM | zacks.comFTSE 100 Live 29 September: Index nears record, GSK shares rise on CEO changeOctober 1 at 11:32 PM | standard.co.ukSGSK CEO Emma Walmsley Says Drugmaker Is ‘Betting Big’ on the USOctober 1 at 6:32 PM | msn.comPark Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSKOctober 1 at 4:41 AM | marketbeat.comCentral Pa. part of GSK $30B investment in U.S. manufacturingSeptember 30 at 8:22 PM | cpbj.comCGSK (NYSE:GSK) Shares Up 4% - What's Next?September 30 at 12:34 PM | marketbeat.comGSK’s first female CEO Emma Walmsley to exit, succeeded by Luke MielsSeptember 30 at 6:36 AM | thenews.com.pkTSound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSKSeptember 29, 2025 | marketbeat.comGSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield GroupSeptember 29, 2025 | marketbeat.comGSK turns to insider to be next CEO — and the stock ralliesSeptember 29, 2025 | marketwatch.comGSK: CEO Emma Walmsley to step down after eight-year tenureSeptember 29, 2025 | yorkshirepost.co.ukYLONDON BRIEFING: AstraZeneca plans listing changes; GSK names next CEOSeptember 29, 2025 | lse.co.ukHeard on the Street Friday Recap: Another Dose of TariffsSeptember 29, 2025 | wsj.comGSK chief executive Emma Walmsley to leave role as chief commercial officer Luke Miels steps upSeptember 29, 2025 | irishexaminer.comIGSK’s boss Emma Walmsley to step down after eight-year tenureSeptember 29, 2025 | msn.comGSK CEO Walmsley to step down, be succeeded by company’s commercial leadSeptember 29, 2025 | statnews.comSGSK chief Emma Walmsley to step downSeptember 29, 2025 | ft.comGSK Names Luke Miels to Succeed CEO Emma WalmsleySeptember 29, 2025 | msn.comGSK CEO Walmsley to step down, Luke Miels to take over in JanuarySeptember 29, 2025 | msn.comGSK’s Walmsley to Exit as Drugmaker Grapples With Pipeline WorrySeptember 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK Company DescriptionsGSK NYSE:GSK$43.30 -0.39 (-0.89%) Closing price 03:59 PM EasternExtended Trading$43.38 +0.08 (+0.18%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play General Dynamics Hits New Highs: Why It Might Keep Climbing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
